Prime Medicine, Inc. (PRME)
Prime Medicine, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Cambridge, MA, US. The stock last traded at $3.22, down 1.20% on the session, giving a market capitalisation of $581.8M. On trailing twelve-month figures it carries a trailing P/E of -2.93, a net margin of -4613.1%. Its beta of 2.31 implies it has historically moved more than the broad market.
Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combines a unique Prime Editor protein—a hybrid composed of a Cas protein and a reverse transcriptase enzyme—with a specialized pegRNA molecule. This pegRNA plays a crucial role by both guiding the Prime Editor to a precise location within the genome and providing the essential template for introducing the desired modification to the target DNA sequence. The company, founded in 2019, maintains its headquarters in Cambridge, Massachusetts.
Prime Medicine, Inc. is most often compared with the following Healthcare names: